Scleroderma;Esclerodermia

Medicina Clinica

Volumn 122, Issue 11, 2004, Pages 418-419

  Fonollosa Pla, Vicent ^a   Simeón Aznar, Carmen Pilar ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOGLOBULIN; METHOTREXATE;

CLINICAL FEATURE; DISEASE ASSOCIATION; EDITORIAL; HUMAN; PROGNOSIS; RAYNAUD PHENOMENON; SCLERODERMA; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 2442539441     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059540     Document Type: Editorial

References (19)

1. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-54.
2. Schachna L, Wigley FM. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 2002;14:686-93.
3. Jun JB, Kuechle M, Harlan JM, Elkon KB. Fibroblast and endotelial apoptosis in systemic sclerosis. Curr Opin Rheumatol 2003;15:756-60.
4. Solans R, Motta C, Solá R, LaVille AE, Lima J, Simeón CP, et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis. Evidence of free radical-injury. Arthritis Rheum 2000;43:894-900.
5. Takehara K. Pathogenesis of systemic sclerosis. J Rheumatol 2003;30: 755-9.
6. Lima J, Fonollosa V, Fernández-Cortijo J, Ordi J, Cuenca R, Khamashta MA, et al. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 1991; 18:1833-6.
7. Medsger TA, Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29:255-73.
8. Candell J, Armadans LL, Simeón CP, Castell J, Fonollosa V, García del Castillo H, et al. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum 1996;39:1138-45.
9. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma. Arthritis Rheum 2000;43:444-51.
10. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis. Demographic, clinical, and serologic features and survival in 1012 italian patients. Medicine (Baltimore) 2002;81: 139-53.
11. Scussel-Lonzeti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 french canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002;81:154-67.
12. Simeón CP, Armadans LL, Fonollosa V, Vilardele M, Candell J, Tolosa C, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997;56:723-8.
13. Steen VD, Medsger TA Jr. Improvement on skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44: 282B-35.
14. Simeón CP, Armadans LL, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003;42:71-5.
15. Harris ML, Rosen A. Autoimmunity in scleroderma: the origin, pathogenic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003;15:778-84.
16. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002;29:2371-8.
17. Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW. Systemic sclerosis-associated pulmonary hypertension. Short and long-term effects of epoprostenol (Prostacyclin). Arthitis Rheum 1999;42:2638-45.
18. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
19. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antoagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54.